Identification
Instrument name
TXCELL
Symbol
TXCL
ISIN code
FR0010127662
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
ICB
Biotechnology
Activity description

<p>
TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.<br />
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).</p>

Operation
IPO date
IPO type
Initial Public offering
Catégorie
IPO
Capital raised
16.2